|
Pathogen (Target Population)
|
Type of Vaccine
|
Cost of Development ($ millions)
|
Probability of Successful Development
|
|
Dengue virus (Infants and children in endemic areas; travelers to endemic areas)
|
Attenuated live vector virus containing gene for broadly cross-reacting protective antigen
|
25
|
0.75
|
|
Escherichia coli (enterotoxigenic) (Infants<6 months)
|
A combination of purified colonization factor antigens and possibly other antigens
|
25
|
0.50
|
|
Genetically engineered attenuated strains
|
25–50
|
0.70
|
|
Hemophilus influenzae type b (Infants)
|
Conjugated polysaccharide
|
15
|
0.90
|
|
Hepatitis A virus (Susceptibles of all ages; routine for preschool children)
|
Attenuated live virus
|
15
|
0.95
|
|
Polypeptide recombinant vaccine produced in yeast
|
25
|
0.95
|
|
Hepatitis B virus (Areas with high perinatal infection: all infants at birth (if possible). Other areas: all infants, simultaneous with other vaccinations, at earliest possible age)
|
Polypeptide produced by recombinant DNA technology
|
5
|
0.99
|
|
Japanese encephalitis virus (Children in epidemic and endemic areas; foreign visitors to epidemic regions)
|
Inactivated virus produced in cell culture
|
50
|
0.50
|
|
Mycobacterium leprae (Immunoprophylactic: all children in endemic areas. Immunotherapeutic: all recently infected individuals)
|
Armadillo-derived M. leprae
|
25
|
0.50
|
|
Neisseria meningitidis (Infants, 3 to 6 months)
|
Conjugated capsular polysaccharides. Groups A,C,Y, and W135
|
30
|
0.50 (dependent upon success in developing conjugation procedures with other vaccines)
|
|
Parainfluenza viruses (Infants)
|
Trivalent, subunit vaccine (which must contain fusion proteins)
|
25
|
0.80
|
|
Plasmodium spp. (All infants at risk, military personnel, travelers)
|
Plasmodium falciparum, synthetic or recombinant sporozoite antigen preparation
|
25
|
0.50
|
|
Multivalent synthetic or recombinant sporozoite antigen preparation (P. falciparum, P. vivax, P. ovale, P. malariae)
|
35
|
0.50
|
